Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity

This healthcare company is targeting a lucrative market…

| More on:

Image source: Getty Images

The Rhythm Biosciences Ltd (ASX: RHY) share price is on fire on Tuesday morning.

At the time of writing, the cancer diagnostics technology company’s shares are up 15% to $1.90.

This means the Rhythm Biosciences share price is now up an impressive 68% in 2021.

Why is the Rhythm Biosciences share price rocketing higher today?

Investors have been bidding the Rhythm Biosciences share price higher today following the release of an update relating to its ColoSTAT product.

ColoSTAT is a simple, low-cost, blood test for global mass market detection of colorectal cancer. The company notes that colorectal cancer is the third most common cancer in men and the second most common in women globally, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

According to today’s release, the company has achieved a major regulatory milestone for the commercialisation of ColoSTAT. The product has been granted CE Mark and fully conforms with the European Directives for IVD Medical Devices.

Management highlights that this critical regulatory achievement is a result of robust and stringent analytical testing and adherence to design and development procedures.

Rhythm Biosciences’ CEO, Glenn Gilbert, said: “The achievement of this regulatory milestone continues to validate our commercial pathway into significant global markets, with Europe alone representing a massive addressable population of over 231 million people. This significant achievement represents an initial step change in the Company and is a testament to the dedication and commitment of the entire Rhythm team. Rhythm is currently assessing its commercialisation options to market ColoSTAT into Europe.”

What’s next?

The company notes that being granted CE Mark was a critical component in its commercial plan and priority market entry strategy. It allows Rhythm to commercialise, market and sell ColoSTAT in a significant global market across Europe and other countries which recognise CE.

Management estimates that this customer market currently represents an addressable screening population of over 231 million people, with a combined value of US$12 billion.

Should you invest $1,000 in Rhythm right now?

Before you consider Rhythm, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Rhythm wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers